1. Introduction {#sec1-genes-09-00136}
===============

The main goal of gene therapy is to use nucleic acids as drugs to treat a wide range of both inherited and acquired diseases. Nucleic acids are large anionic molecules that have great difficulties crossing membrane barriers and usually require the use of vectors or carriers in order to ensure effective transport. Likewise, nucleic acids are easily degraded within biological fluids and this enormously limits their half-life and cell availability. Nowadays, two different types of vectors are being employed to circumvent this situation: viral vectors \[[@B1-genes-09-00136]\] and non-viral vectors (which are safer but usually less effective).

Since safety is always a priority concern with all drugs destined for human use, it must be underscored that the negative effects associated with these vectors are related to the viral or bacterial sequences that accompany the therapeutic nucleic acids and the carriers (such as proteins or polymers) required to protect them and facilitate their intracellular access.

Although side effects of viral systems are more relevant than in non-viral systems, both types of vectors show toxicity to some degree. In this sense, the hydrodynamic delivery procedure, based on the rapid/pressurized injection of a large volume of gene solution, represents a great breakthrough in the safe management of gene therapy, since it permits the efficient delivery of nucleic acids into the cell without the use of carriers (i.e., avoiding potential toxicity events derived from carriers or vectors). The hydrodynamic procedure has gained renewed interest derived from its potential use in CRISPR/Cas9 gene constructs for gene edition purposes, or in previously formed complexes for transfer to target organs. The procedure would allow access to the cell nucleus, facilitating the interaction of the RNA guide with the complementary sequence and circumscribing CRISPR effects to the target organ alone---thereby partially avoiding the possible systemic effects.

Unfortunately, this successful procedure first developed in murine models is accompanied by important hemodynamic changes in the animal that make it incompatible with clinical practice. This special circumstance makes adaptation of the procedure in large animals a priority for its clinical translation. Overcoming this limitation would be a great advance in allowing the hydrodynamic procedure to be successfully applied to the clinical setting. In the present work, we describe (from our perspective) the efforts made in this field, with the aim of adapting the procedure to achieve therapeutic results, employing suitable experimental conditions for clinical practice.

2. Hydrodynamic Model {#sec2-genes-09-00136}
=====================

During the last decade of the 20th century, different strategies to transfer human genes to mouse hepatocytes in vivo were developed \[[@B1-genes-09-00136]\], employing both viral and non-viral vectors. Regarding the latter, the viability of the delivery of genes encapsulated in small unilamellar liposomes \[[@B1-genes-09-00136]\] capable of accessing the hepatocytes was evaluated. The expression of the human alpha-1-antitrypsin (*AAT*) gene was significantly extended when transfection was associated with partial hepatectomy \[[@B2-genes-09-00136]\] and was improved and prolonged (approximately 50 ng/mL) by employing liposomes encapsulating nuclear location sequences targeted to specific liver cell receptors \[[@B3-genes-09-00136]\]. However, the final efficacy achieved was several orders of magnitude lower than the values expected to mediate therapeutic benefits. Fortunately, naked DNA transfection employing the hydrodynamic procedure through the mouse tail vein afforded promising results \[[@B4-genes-09-00136]\]. Later, in 2003, stationary therapeutic plasma levels of protein (\>1 mg/mL) during long periods \[[@B5-genes-09-00136]\] were achieved. The results obtained showed that this new procedure employing naked DNA achieved higher (more than 4 orders of magnitude or 10,000-fold) efficacy than another approach employing non-viral carrier strategies and evidenced that viral and non-viral systems may achieve equivalent therapeutic efficacies. For these reasons, knowing the hydrodynamic procedure and identifying the mechanisms of gene delivery and the corresponding molecular response are of enormous interest in facilitating clinical translation of the method in a precise, safe and efficient manner. In this chapter, the procedure of hydrodynamic injection, its discovery and development and the underlying mechanism of gene delivery are described.

2.1. Hydrodynamic Injection of Naked Nucleic Acids {#sec2dot1-genes-09-00136}
--------------------------------------------------

Preliminary studies employing naked DNA evidenced that when using specific conditions for intravascular injection, nucleic acids can be effectively transfected in vivo without any carrier or vector, since: (a)The DNA reached the muscle and was expressed \[[@B6-genes-09-00136]\].(b)The mouse liver could be transfected in vivo by the pressurized injection of a hyperosmotic solution containing naked human growth hormone (hGH) DNA through the portal vein \[[@B7-genes-09-00136]\], achieving plasma protein levels (65 ng/mL) 50-fold higher than the normal basal values.(c)High expression levels of tracer genes were achieved in the hind limb muscle of rats by pressurized DNA injection through the iliac artery \[[@B8-genes-09-00136]\].

The "hydrodynamic procedure" ([Figure 1](#genes-09-00136-f001){ref-type="fig"}) was definitely described in 1999 \[[@B9-genes-09-00136]\] as the rapid injection (5--7 s) of a large saline solution volume (1/10 body weight) containing naked DNA through the mouse tail vein. In a typical experiment employing a mouse of 20 g body weight, 2 mL of saline DNA (0.5--5 mg/kg) solution is injected in 5 s. The procedure is especially effective for liver gene transfer \[[@B10-genes-09-00136],[@B11-genes-09-00136],[@B12-genes-09-00136]\] but also for transfer to other organs such as kidney \[[@B13-genes-09-00136]\], skeletal muscle \[[@B14-genes-09-00136],[@B15-genes-09-00136]\] and cardiovascular tissue \[[@B16-genes-09-00136]\]. After hydrodynamic injection, a rapid increase in plasma levels of liver enzymes AST and ALT is observed, which is quickly normalized within one to three days. On the other hand, the animals tolerate the administration of multiple doses, without apparently affecting liver function or causing any other metabolic effects and/or injuries in other organs \[[@B9-genes-09-00136],[@B14-genes-09-00136]\].

The main limitation of the procedure arises from the hemodynamic changes induced by hydrodynamic injection. In the mouse, the rapid injection of 2 mL of saline solution doubles its volemia and consequently results in cardiac pump failure due to the sudden increase in preload.

The hemodynamic impact of injection is important. However, although the animals suffer immediate collapse due to transient cardiac overload, they rapidly recover within the first 5 min. This is due to rapid normalization of cardiac preload, which is possible thanks to the high heart rate of mice. However, these hemodynamic changes would not be compatible with human use and represent the first and main limiting step that must be circumvented in order to allow clinical translation of the hydrodynamic procedure.

2.2. Delivery Mechanism {#sec2dot2-genes-09-00136}
-----------------------

The mechanism underlying the hydrodynamic transfection (hydrofection) of genes in the murine model \[[@B10-genes-09-00136],[@B11-genes-09-00136],[@B12-genes-09-00136]\] has not been elucidated to date. Knowledge of this mechanism will contribute to better understand and adapt the procedure to large animals under conditions compatible with clinical use.

Since the mechanism must be common in all regions, except in relation to some organ particularities (e.g. resilience, vascularization, size, type of vascular endothelium, etc.) that define the injection conditions (volume, flow rate, DNA concentration, etc.) in each case, the present review focuses on the advances achieved in liver gene transfer. It must be underscored that although the experimental stages and results have been clearly confirmed, correct interpretation of the entire process has not yet been corroborated.

The main findings to date in relation to the hydrofection mechanism are described below: (1)The first experiments employing tracer genes and immunohistochemical methods to identify the liver expression of exogenous genes showed expression to be mainly located in central vein areas, thereby supporting that the inversion of flow sense mediates retrograde backflow to the liver and this could be involved in the mechanism of action ([Figure 1](#genes-09-00136-f001){ref-type="fig"}).(2)Hydrodynamic injection mediates a remarkable pressure increase in the cava vein, since the tail vein is its direct tributary. This is due to the fact that the administration of a large volume (2 mL in the mouse) in this area (cardiac preload) means doubling the volemia---thereby generating an important pressure increase. This process inverts the pressures at cava vein level with respect to the portal vein and causes retrograde backflow of blood to the liver. This idea is supported by experimental data. The simultaneous measurement of pressures in portal and cava vein areas shows that inversion of portal versus cava pressures exists both during injection and at least 5 min later.(3)Flow inversion has been observed by intravital microscopy \[[@B17-genes-09-00136]\] during hydrodynamic injection and minutes later. During rapid injection, flow is inverted and remains static but pulsatile during the first minute. Anterograde flow recovers slowly and progressively until normalization is reached within 5 or 6 min after hydrodynamic injection. It is assumed that the transfection process occurs during this short period of time.(4)Ultrastructural morphological changes \[[@B17-genes-09-00136]\] in liver tissue during hydrodynamic injection evidence that the hydrodynamic force exerted upon the liver sinusoids promotes vascular distension, widening sinusoidal pore diameter and the endothelial junctions and facilitating access of the DNA solution to the likewise widened virtual Disse space ([Figure 2](#genes-09-00136-f002){ref-type="fig"}). This process allows interaction of the aqueous solution with hepatocytes in a high-pressure scenario that promotes the formation of multiple endocytic vesicles without solution of continuity of the cell membrane, as observed by electron microscopy. This excludes the possibility of DNA access to the hepatocyte through membrane disruption and the formation of large permissive pores instead of endocytic vesicles. Moreover, large pores could compromise hepatocyte viability. It must be underscored that the existence of narrow junctions (tight junctions) among hepatocytes limits free DNA diffusion through the intercellular spaces. Thus, hepatocyte hydrofection (gene transfer mediated by hydric forces) could be due to DNA saline solution entry into the hepatocyte, which is mediated by the hydrodynamic force exerted.(5)Although the possibility that part of the DNA may access the hepatocyte through a receptor-mediated process \[[@B7-genes-09-00136]\] cannot be discarded, this process would contribute only slightly to the efficiency of hydrodynamic delivery.(6)The early experimental data, employing molecules of different size and weight, as well as recent observations employing colloidal gold nanoparticles of known diameter and electron microscopy \[[@B18-genes-09-00136],[@B19-genes-09-00136]\], support the idea that hydrofection implies a passive process without energy consumption but driven by hydrodynamic force through more permissive sites of the cell membrane, including endocytic vesicles. The dimension of the membrane sinusoids, depending on the species, can be as much as 100 nm in diameter \[[@B20-genes-09-00136]\]. However, only particles with diameters smaller than 10 nm can access the cell \[[@B21-genes-09-00136]\], whereas larger particles are virtually refractory to hepatocyte entry but can be observed within the cytoplasm of phagocytic cells (Kupffer cells). This interpretation of the delivery mechanism combines DNA access to the hepatocyte through the cell membrane with no important liver toxicity and justifies the acute plasma increase in transaminases due to marginal cell destruction, which is rapidly reverted within the first days after hydrodynamic injection. This suggests that injured cells are eliminated, whereas the efficiency of transfection remains in those cells in which DNA has gained access in a less aggressive manner. Nevertheless, further studies are needed to establish the exact mechanism of gene delivery mediated by the hydrodynamic procedure.

3. Gene Transfer Applications {#sec3-genes-09-00136}
=============================

Gene therapy offers the possibility of treating any type of disease whose aetiology is well defined at molecular level. Once the cause of an illness is known, it is possible to specifically design a gene construct with the ability to improve the pathological scenario and then transfer it with availability for being transcribed and translated. Among the different procedures proposed, hydrodynamic gene transfer in the mouse has been shown to be efficient for transferring genes to different organs in a safe manner and in some cases with high efficacy. This fact makes it possible to expand the potential therapeutic applications of the technique. In this regard, the hydrodynamic procedure for gene transfer has been widely applied for treating a range of diseases in different mouse organs such as muscle and liver. Next, different applications for a wide range of both acquired and inherited diseases are described.

3.1. Muscle {#sec3dot1-genes-09-00136}
-----------

The most widely employed procedures for gene transfer to muscle were the direct intramuscular injection and vascular injection of gene constructs through the hind limb vein.

Muscular tissue has served as a target of this therapy since its implantation. Zhang et al. \[[@B22-genes-09-00136]\] injected a DNA plasmid with the entire murine dystrophin gene into the skeletal muscles of the hind limbs of the Duchenne mouse model. These authors achieved 18--20% of the normal levels of dystrophin protein with 11--16% expressing myofibres. Zhang et al. \[[@B23-genes-09-00136]\] in turn injected a plasmid encoding siRNA to silence nicotinic acetylcholine receptor α1 to heart and 78% knockdown was achieved 16 weeks after transfection. Bostrom et al. \[[@B24-genes-09-00136]\] transferred peroxisome proliferator-activated receptor-gamma coactivator-1alpha (*PGC1α*) gene to skeletal muscle and reported protein expression, which improved obesity and glucose metabolism. As a proof of concept, Guess et al. (2013) \[[@B25-genes-09-00136]\] injected a plasmid encoding tracer siRNA to study the distribution of hind limb gene delivery and observed disperse expression across multiple hind limb muscle groups. Mukumoto et al. \[[@B26-genes-09-00136]\] compared hydrodynamic liver and intramuscular gene delivery procedures and the mice receiving intramuscular injections yielded better results than mice receiving hydrodynamic injections. Nagata et al. \[[@B27-genes-09-00136]\] transferred insulin-like growth factor (IGF-1) carried in a polyplex nanomicelle through hydrodynamic hind limb injection in mice with sciatic nerve injury and reported improved motor function for at least 25 days.

3.2. Liver {#sec3dot2-genes-09-00136}
----------

Given the efficiency of hydrodynamic injection in transferring genes to the liver, this was the most widely employed strategy. Different modifications seeking to enhance its efficacy were partial hepatectomy, integrative plasmids and the use of targeting.

One of the most extensively studied disorders with a potential for treatment with non-viral gene therapy and for which the hydrodynamic procedure has shown the most promising outcomes is probably hAAT deficiency \[[@B28-genes-09-00136]\]. The entire human *hAAT* gene encapsulated in liposomes of different diameters was transferred to mice. Small liposomes (54 ± 11 nm in diameter) carried the gene to parenchymal cells, mediating the presence of protein in plasma seven days after treatment. Subsequently, Aliño et al. \[[@B1-genes-09-00136],[@B29-genes-09-00136]\] reported hAAT protein expression in liver over two weeks, achieving plasma concentrations of up to 160 ng/mL after single-dosing plus liver regeneration induced by partial hepatectomy. Additional studies \[[@B2-genes-09-00136]\] reported anionic liposomes to mediate more durable protein expression, reaching plasma levels of over 100 ng/mL for more than five months. In 2000, Zhang et al. \[[@B4-genes-09-00136]\] employed the hydrodynamic procedure \[[@B9-genes-09-00136],[@B30-genes-09-00136]\] to transfer the *hAAT* gene and reported the plasma expression of 2--5 µg/mL of protein for six months with peak levels of 0.5 mg/mL. In 2001, Dasi et al. \[[@B3-genes-09-00136]\] injected *hAAT* gene encapsulated within asialofetuin liver-targeted liposomes, reporting stationary plasma levels of approximately 50 ng/mL of hAAT protein during more than 12 months. The same group \[[@B5-genes-09-00136]\] transferred the entire genomic *hAAT* gene driven by its natural promoter and reported long-term (\>6 months) therapeutic plasma levels (\>1 mg/mL) of human protein in mice. Immunohistochemical studies revealed that no more than 5--10% of the liver cells were producing the exogenous protein. Furthermore, it was observed that the injection widened the Disse space and induced the formation of massive endocytic vesicles within the hepatocytes that could facilitate DNA access into the cells. Hydrofection was not only shown to be efficient for *hAAT* gene transfer in mice but also safe \[[@B31-genes-09-00136]\]---without significantly modifying the levels of liver enzymes or the expression of other genes.

Haemophilia is another ideal candidate for successful treatment via hydrodynamic gene transfer, since it is an inherited monogenic disease with the liver as specific target organ for gene therapy. Schuttrumpf et al. \[[@B32-genes-09-00136]\] used human coagulation factor IX in knockout (KO) mice and achieved a plasma expression of 100% normal levels of fully functional FIX protein. In 2009, Keravala et al. \[[@B33-genes-09-00136]\] transferred phiC31 integrase and the *hFIX* gene to FIX knockout mice. They reported therapeutic plasma levels of protein over six months and functional activity in the correction of bleeding after tail clipping. Likewise, in 2011, Kim et al. \[[@B34-genes-09-00136]\] reported long-term expression of hFIX (above 500 ng/mL) and clotting activity for seven months in FIX knockout mice after hydrodynamic injection without genome integration. Given the positive outcomes obtained, researchers evaluated gene constructions with greater potential to be employed in humans. In this sense, Schuttrumpf et al. \[[@B35-genes-09-00136]\] compared the efficacy of transgene expression of classic plasmids versus minicircle vectors in FIX knockout mice over time. Both systems mediated therapeutic plasma levels, with minicircles reaching longer-lasting expression. Having demonstrated the potential application of hydrofection to treat haemophilia B, Matsui et al. \[[@B36-genes-09-00136]\] employed this strategy to test its possible use in haemophilia A. Accordingly, these authors transferred the entire human FVIII cDNA in a piggyback transposon to mice and reported protein plasma expression (40 mU/mL) for more than 300 days, with functional activity in FVIII knockout mice.

The metabolic disorders diabetes, cholesterolemia and obesity have been the subject of hydrofection studies conducted to evaluate potential applications of the technique to these diseases. In this sense, Holm et al. \[[@B37-genes-09-00136]\] transferred Short-Chain AcylCoA Dehydrogenase Deficiency (SCAD) cDNA to SCAD knockout mice and reported 30% of SCAD normal levels during 31 days. Another metabolic disease that has been evaluated for treatment using the hydrodynamic procedure is familial hypercholesterolemia. Turunen et al. \[[@B38-genes-09-00136]\] injected sleeping beauty transposons carrying LDLR and VLDLR to LDLR-deficient mice and observed initial reductions in plasma cholesterol of 17--19%, with significant stabilization of cholesterol levels during at least 6.5 months. Jiang et al. \[[@B39-genes-09-00136]\] hydrofected leptin and Ciliary Neurotrophic Factor (*CNTF*) genes in mice to evaluate their role in preventing obesity and observed significant reductions in food intake and weight. Mukumoto et al. \[[@B26-genes-09-00136]\] in turn evaluated the effect of the hydrodynamic and intramuscular injection of a plasmid encoding *IL-6* gene upon diet-induced obese mice. These authors observed lower weight and fat accumulation in treated mice, lesser weight gain and reduced mRNA expression of metabolism-related genes. González-Muniesa et al. \[[@B40-genes-09-00136]\] hydrofected a plasmid encoding the *UCP-1* gene---a mitochondrial protein with the ability to uncouple mitochondrial respiration---and reported that this strategy can mediate the expression of exogenous genes within the liver mitochondrion, opening a wide range of applications. As an approach to explore the potential application of hydrofection to treat type 1 diabetes, He et al. \[[@B41-genes-09-00136]\] used insulin cDNA in a plasmid and as a sleeping beauty transposon in diabetic mice and reported the expression of insulin in both plasma and liver tissue, as well as blood glucose reduction and weight loss control. Fukushima et al. \[[@B42-genes-09-00136]\] transferred the adiponectin gene, which is involved in glucose and lipid metabolism and observed a decrease in circulating glucose (due to the elevated glucose uptake) and triglycerides. Gao et al. \[[@B10-genes-09-00136]\] also studied the potential use of hydrodynamic gene transfer to treat and/or prevent obesity. Mice fed a high fat diet were treated with *mIL10* gene, whose overexpression prevented weight gain and glucose intolerance. Ma et al. \[[@B43-genes-09-00136]\] employed a similar model to transfer adiponectin and/or its receptor 2 gene into skeletal muscle and liver and reported similar results---with intramuscular injection yielding slightly better outcomes. Vakili et al. \[[@B44-genes-09-00136]\] studied the potential benefit of the hydrodynamic procedure for treating type 2 diabetes in diabetic mice. They transferred small hairpin RNA (shRNA) to silence the overexpression of protein tyrosine phosphatase 1B (PTP1B), present in diabetes. The expression of PTP1B decreased by 84% and the plasma glucose levels also diminished. Hydrodynamic injection in experimental diabetic mice has also been used as a screening test to identify therapeutic targets \[[@B45-genes-09-00136]\]. Gao et al. \[[@B11-genes-09-00136]\] transferred FGF21 cDNA and evaluated its effect on mice fed a high fat diet---reporting reduced obesity and body weight gain and the alleviation of liver steatosis. In a similar way, Ma et al. \[[@B12-genes-09-00136]\] injected the *IL-6* gene to high fat diet obese mice in order to evaluate its potential role in the treatment of obesity, observing increased expression of lipolysis genes, a reduction of body weight and improved obesity-associated steatosis.

3.3. Other Inherited Diseases {#sec3dot3-genes-09-00136}
-----------------------------

Monogenic inherited diseases are perfect target diseases for gene therapy, since treatment consists of repairing the mutated gene and/or implementing the correct gene to restore the normal phenotype. One of these disorders is mucopolysaccharidosis (MPS), which comprises a group of conditions caused by malfunctioning of lysosomal storage. Camassola et al. \[[@B46-genes-09-00136]\] injected α-L-idurodinase (IDUA) enzyme cDNA in a model of MPS I mouse and reported efficient transgene expression, which reduced the levels of accumulated glycosaminoglycans (GAGs). In a similar way, Richard et al. \[[@B47-genes-09-00136]\] transferred the β-glucuronidase gene through hydrodynamic injection or intramuscular injection to treat MPS VII and reported a reduced accumulation of GAGs. In turn, in 2014, Quiviger et al. \[[@B48-genes-09-00136]\] injected N-sulfoglucosamine sulfohydrolase (SGSH) cDNA in a model of MPS IIIA mouse and observed high serum levels of protein, with the correction of GAG accumulation. Von Willebrand disease (VW) is another inherited disease studied as a target for hydrodynamic gene therapy. Pergolizzi et al. \[[@B49-genes-09-00136]\] used murine VWF cDNA and achieved the normalization of bleeding time 48 h after gene delivery in mice. Sickle-cell disease (SCD) has also been evaluated as a therapeutic target for hydrodynamic gene transfer. Belcher et al. \[[@B50-genes-09-00136]\] transferred a sleeping beauty transposon carrying the wild type rat *Hmox-1* gene in SCD mice, which presented hypoxia-induced stasis inhibition. Phenylketonuria (PKU) is a monogenic disease of hepatic origin defined by phenylalanine hydroxylase (PAH) deficiency. Viecelli et al. \[[@B51-genes-09-00136]\] and Grisch-Chan et al. \[[@B52-genes-09-00136]\] injected a minicircle encoding PAH cDNA to PKU mice and achieved normalized blood phenylalanine for more than one year. Such long-term expression was suggested to be due to the persistence of minicircles within hepatocytes (probably but not confirmed, as episomes).

3.4. Infectious Diseases {#sec3dot4-genes-09-00136}
------------------------

The liver can be affected by other acquired and potentially life-threatening disorders. One of the most important is hepatitis, which can have several causes, such as inflammatory alterations, viral infection or a fulminant process characterized by liver inflammation and autoimmune responses. The hydrofection procedure has been employed to create models of hepatitis B (HBV) and hepatitis C (HCV) in mice, making it possible to study the pathology and immune response. In this regard, Yang et al. \[[@B53-genes-09-00136]\] administered a sleeping beauty transposon carrying the HBV genome and evaluated its expression and the response of the immune system against it. In addition, a model of hepatitis C was developed by McCaffrey et al. \[[@B54-genes-09-00136]\], injecting HCV genomic RNA. Kim et al. \[[@B55-genes-09-00136]\] transferred HCV-core-specific siRNA to mice with HCV to limit viral gene expression, silencing viral expression 65--75% two days after injection. Viral infections (hepatitis viruses, adenoviruses) and other causes such as toxins, can produce liver failure. In these cases, the most important concern is to protect hepatocytes from apoptosis. With this purpose, Zender et al. \[[@B56-genes-09-00136]\] injected siRNAs to silence Cas8, which plays an important role in cell apoptosis and reported one-month survival of mice when treated with anti-apoptosis siRNA versus one day survival in the case of the untreated controls. Fulminant hepatitis and liver inflammation have been studied for gene therapy treatment and researchers have proposed different strategies. In this respect, osteopontin (OPN) has been suggested to increase in fulminant hepatitis and Saito et al. \[[@B57-genes-09-00136]\] evaluated the benefit of silencing the mentioned gene by injecting anti-OPN siRNA, resulting in amelioration of liver tissue injury. Xu et al. \[[@B58-genes-09-00136]\] in turn observed that the ectopic expression of B7-H4-Ig fusion protein mediated by hydrodynamic transfer could suppress liver necrosis in mice with induced hepatitis. In a model of hepatitis, Bulau et al. \[[@B59-genes-09-00136]\] transferred the *IL-37* gene and observed significant reductions in the expression of proinflammatory genes (*IL-1*, *IL-6* and others). Shashidharamurthy et al. \[[@B60-genes-09-00136]\] showed the hydrodynamic delivery of human FcγR-Ig dimers to block immune-complex mediated inflammation in mice. Anavi et al. \[[@B61-genes-09-00136]\] employed a model of induced liver inflammation mediated by the impairment of hypoxia-inducible factor 1 (HIF-1). Transfer of *HIF-1* gene to these iNOS knockout mice permitted its expression in liver, ameliorating the liver damage. The NK2GD receptor is another factor related to the initiation and maintenance of liver inflammation. In this regard, Huang et al. \[[@B62-genes-09-00136]\] employed three specific short hairpin RNAs to silence three major ligands of NKG2D on hepatocytes, achieving the downregulation of those ligands that alleviated fulminant hepatitis. Another strategy applicable in liver inflammation consists of silencing proinflammatory cytokines such as IL-6. In this sense, Gortz \[[@B63-genes-09-00136]\] injected cDNA encoding a receptor fusion protein to inhibit IL-6 that allowed blocking of the acute phase of liver inflammation. Once the inflammatory process has been stopped and even reverted, liver tissue repair could be necessary. This was explored by Tsai et al. \[[@B64-genes-09-00136]\], who demonstrated that the overexpression of fibroblast growth factor 7 (*FGF7*) mediated by hydrofection could notably promote liver cell proliferation after partial hepatectomy.

Although the aforementioned diseases have been the conditions most widely studied for treatment through hydrodynamic gene transfer, they are not the only ones. In effect, researchers have evaluated potential application of the procedure to many other different inherited and acquired diseases.

3.5. Cancer {#sec3dot5-genes-09-00136}
-----------

One of the major acquired disorders investigated for potential treatment using hydrodynamic gene transfer is cancer. Different approaches have already been adopted. Wu et al. \[[@B65-genes-09-00136]\] designed a gene construct carrying a member of the TNF family with the capacity to induce apoptosis in specific human tumours. Its transfer in SCID mice with human breast tumours resulted in tumour regression and reduced growth compared to the controls. Yazawa et al. \[[@B66-genes-09-00136]\] transferred the foetal liver kinase 1 (*Flk-1*) gene, a receptor of vascular endothelial growth factor (VEGF), aiming to block tumour angiogenesis. This permitted a decrease in the formation of new vessels and suppression of the growth of pre-existing tumours. Another strategy involved use of the interferon gamma gene, with the ability to inhibit the formation of metastases. Following this strategy, Miyakawa et al. \[[@B67-genes-09-00136]\] injected a plasmid encoding a fusion protein formed by IFN-γ and serum albumin and this permitted prolongation of the serum half-life of the protein. Ando et al. \[[@B68-genes-09-00136]\] confirmed these results and demonstrated that a reduced number of CpG motifs in gene constructs resulted in more durable transgene expression. In 2013, Miyakawa et al. \[[@B69-genes-09-00136]\] designed another plasmid encoding a fusion protein containing IFN-γ and albumin binding protein that could extend the circulating half-life of IFN, retaining 40--50% of biological activity. With the aim of avoiding the systemic side effects related with IFN, Ando et al. \[[@B70-genes-09-00136]\] designed constructions encoding fusion proteins of IFN and heparin binding domain in order to target the liver. With this strategy, they achieved tumour growth suppression without systemic adverse effects. Given the interest of immunotherapy strategies against cancer, Ochoa et al. \[[@B71-genes-09-00136]\] constructed an expression plasmid encoding IL15 and Apo A1 and co-administered it with a plasmid carrying the sushi domain of IL15Rα. These authors achieved an increase in NK cell count, as also reported by Barao et al. \[[@B72-genes-09-00136]\] and an increase in the number of memory CD8 lymphocytes in blood, spleen and liver---with modest therapeutic effects against colon cancer, for 60 days. Sun et al. \[[@B73-genes-09-00136]\] evaluated the antitumor activity of IL15/sIL15Rα upon Lewis lung tumour growth in lungs, liver and kidney. They transferred this gene as DNA plasmid, reporting inhibition of tumour growth in all three organs and prolonged survival time. Qiu et al. \[[@B74-genes-09-00136]\] in turn injected murine IL28B to the liver, aiming to exert its immunomodulatory effect in lungs. This strategy resulted in a decreased expression of inflammatory proteins in mice exposed to cigarette smoke for 21 days.

3.6. Other Acquired Diseases {#sec3dot6-genes-09-00136}
----------------------------

Many other disorders are potentially amenable to treatment with hydrodynamic gene therapy. For instance, Sondergaard et al. \[[@B75-genes-09-00136]\] employed a hypophysectomised mouse model to transfer the human growth hormone gene. This strategy mediated the normalization of tibia and tail length and body weight gain at the end of the experiment. Lee et al. \[[@B76-genes-09-00136]\] demonstrated long-term and robust parathyroid hormone expression after transferring a PTH cDNA plasmid containing the OC31 integrase, with transgene integration within the genome. Okumura et al. \[[@B77-genes-09-00136]\] proved the efficacy of the chemotaxin 2 (*LECT2*) gene in treating osteoarthritis in knockout mice with induced osteoarthritis. Dermatitis has also been evaluated for the application of hydrodynamic gene transfer. Watcharanurak et al. \[[@B78-genes-09-00136]\] transferred the murine *IFN-γ* gene to mice with early dermatitis and achieved the expression of Treg immunomodulatory cytokines, with improvement of the clinical symptoms. Different types of infection have also been treated with hydrodynamic gene transfer. Wesche-Soldato et al. \[[@B79-genes-09-00136]\] employed septic mice to transfer siRNA against Fas or caspase-8 and recorded decreased mRNA expression and significantly improved survival. Similarly, Tompkins et al. \[[@B80-genes-09-00136]\] designed genic constructs to block highly conserved regions of the influenza A virus and inhibit its replication. The treatment of bacterial infections by gene therapy has also been evaluated. Lu et al. \[[@B81-genes-09-00136]\] reported reduced local skin bacterial counts after human kallistatin transfection in mice previously infected with group A *Streptococcus*.

Given the promising results of the hydrodynamic procedure, other organs and tissues such as the kidneys \[[@B82-genes-09-00136]\] were studied in Fabry mice. The applications of hydrodynamic gene therapy in small animals are summarized in [Table 1](#genes-09-00136-t001){ref-type="table"}.

4. Translation of the Hydrodynamic Method: From Mouse to Large Animals {#sec4-genes-09-00136}
======================================================================

In addition to the murine model, naked gene transfer was employed in rats prior to description of the hydrodynamic procedure. Budker et al. \[[@B8-genes-09-00136]\] showed that high-pressure injection of naked DNA into the hind limb with occluded outflow mediated high expression levels of luciferase in muscle. In the present chapter, we describe the translational process of hydrodynamic procedure through different animal models.

4.1. Rodents {#sec4dot1-genes-09-00136}
------------

Given the promising therapeutic outcomes obtained with the hydrodynamic procedure, research focused on carrying out the translational process of the technique to large animals, with the aim of achieving clinical application. It must be remembered that mouse hydrodynamic injection involved doubling the volemia of the animal within only a few seconds, which induces cardiac overload that cannot be reverted by large animals---with the result of damaging effects. Most of the studies carried out in rats involved conditions similar to those used for mice. However, different adaptations designed to lower the volume of gene solution have been proposed in order to transfer the translation process to the clinical setting. For this purpose, the original hydrodynamic gene transfer procedure had to be adapted to allow safe application in larger animals. One such adaptation was to target reduced areas of the liver.

In a glomerulonephritis (Th1 predominant disease) model in rats, Higuchi et al. \[[@B108-genes-09-00136]\] employed a procedure for gene transfer identical to that described for mouse hydrodynamic injection in order to transfer a plasmid containing viral interleukin 10 (pCAGGS-vIL10). These authors observed reduced mRNA expression of disease related genes for seven days. The application of hydrofection was also tested in liver transplantation \[[@B109-genes-09-00136]\]. For this purpose, CTLA4Ig cDNA was injected in vein, achieving high protein expression that allowed lengthening of graft survival time. Another approach involving the hydrodynamic procedure applied to organ xenotransplantation was described by Miki et al. \[[@B110-genes-09-00136]\] and consisted of depleting the αGal protein from erythrocytes and kidney by injecting Igκ-EndoGalC (a protein with the capacity to remove αGal). The protein was expressed, with elimination of αGal from the vascular endothelium and digestion of 97% of the protein from erythrocytes for seven days. These effects made it possible to protect the treated rats against specific αGal antibodies. The potential applications of the hydrodynamic procedure are so wide that even neurological disorders have been tested \[[@B111-genes-09-00136]\]. In this sense, human EPO cDNA was injected through the tail vein of rats and remarkable plasma levels of protein were detected for at least 14 days. Improvement in cell protection against hypoxia injury and apoptosis in neurons was reported. The technique has also been applied in nephrology in order to evaluate its potential use in limiting the fibrotic process \[[@B112-genes-09-00136]\] triggered after unilateral ureteral obstruction. Antisense oligonucleotides have been injected with the aim of silencing the connective tissue growth factor (*CTGF*) gene. They markedly attenuated the induction of CTGF, fibronectin, fibronectin ED-A and alpha1(I) collagen genes for 14 days, reducing the fibrotic areas.

Other researchers \[[@B113-genes-09-00136]\] have explored different strategies to improve hydrofection efficiency by targeting the right lateral liver lobe of the rat through a portal vein branch, co-administering chloroquine to promote endocytic escape and including the gene into nanoparticles approximately 100 nm in diameter. The authors observed transgene expression, such as luciferase activity. Different studies agree that outflow blockade in the target area is needed, since the portal vein pressure is too low to prevent backflow.

The size limitations of nanoparticles in crossing the cell membrane for gene delivery were confirmed by transmission electron microscopy. The potential application of the hydrodynamic strategy for autoimmune myocarditis was evaluated \[[@B114-genes-09-00136]\] employing equivalent conditions of gene solution volume. To this effect, the interleukin 1 receptor antagonist (*IL1RA*) gene was injected into the tail vein and 17 days later different clinical parameters such as myocarditis areas, heart weight and heart function were seen to have improved compared with the controls. The expression of inflammation-related genes was also reduced. Employing a similar model of experimental autoimmune myocarditis (EAM) in rats, Chang et al. \[[@B115-genes-09-00136]\] found proinflammatory IL-17 cytokine to be overexpressed. They injected the immunosuppressant *IL10-Ig* gene and demonstrated that the expression of this transgene suppressed the expression of IL-17 and other proinflammatory cytokines such as TNF alpha and IL-1. Based on the same model, Chang et al. \[[@B116-genes-09-00136]\] transferred interleukin 18-binding protein (IL18BP). Gene therapy proved effective in controlling EAM, as monitored by a decreased ratio of heart weight to body weight, reduced myocarditis areas, reduced expression of atrial natriuretic peptide, brain natriuretic peptide, IL-17, IFN-γ, IL-6 and IL-10. These effects were likewise suggested to be due to the suppression of IL-17.

On the other hand, the efficacy of gene expression after hydrofection was evaluated in a model of liver transplantation in rats \[[@B117-genes-09-00136]\]. Different volumes of gene solution, types of promoters and different doses of luciferase and hAAT plasmids were used. Transgenes were efficiently expressed, with hAAT protein being present in plasma for at least 21 days (with peak levels on day 7); CMV mediated more efficient gene expression. Larger volumes caused more damage, without associated important improvement in gene expression and a limit in gene expression was observed that could not be overcome by increasing the dose of plasmid administered. As already described in application to mice, liver fibrosis is a target disease for hydrodynamic gene therapy and has also been studied in a rat model \[[@B118-genes-09-00136]\]. Platelet-derived growth factor receptor β subunit (PDGFR-b) was downregulated by gene silencing with siRNA and fibrotic pathways were suppressed, improving the clinical status of the liver.

As part of the hydrodynamic procedure translational process, automation and reproducibility of gene injection are required. With this aim in mind, Suda et al. \[[@B96-genes-09-00136]\] designed a computerized injector that was shown to mediate efficient expression of luciferase in mouse (liver), rat (kidney and muscle) and pig (kidney and liver). Having demonstrated the possibility of gene delivery and transgene expression, researchers sought to improve the efficiency of the procedure. In this regard, ultrasound exposure has been found to enhance (up to 4.5-fold) the efficiency of hydrodynamic-based gene delivery for both luciferase and EPO expression within the rat kidney, without altering the histological structure or impairing physiological function of the treated kidney \[[@B119-genes-09-00136]\]. In another attempt to improve the efficiency of the procedure, the left liver lobe was targeted in rats and outflow occlusion was performed to compare its effect with free-flow control rats \[[@B120-genes-09-00136]\]. Outflow blockade was described as absolutely necessary to obtain efficient outcomes in transgene expression in several orders of magnitude, as determined by luminescence. Cim et al. \[[@B121-genes-09-00136]\] studied the potential interest of the procedure in treating type 1 diabetes in rats. The authors aimed to transdifferentiate hepatocytes into pancreatic β cells to produce insulin. The *Pdx1*, *Ngn3* (*Neurog3*) and *MafA* genes were injected, singly and in combination, to livers of normoglycemic rats. Different expression plasmids bearing DNA and mRNA of these genes were used and insulin was detectable in liver for 28 days. Insulin mRNA levels were close to those observed in the pancreas of normal rats 7 days after treatment but declined thereafter.

It has also been reported that the hydrodynamic procedure may be interesting in application to hypertensive rats. The injection of human hepatocyte growth factor (HGF) has been shown to normalize renal NF-κB activity, proinflammatory cytokines, antioxidant status (GSH, SOD and CAT) and Na+-ATPase activity, reduce renal injury and ameliorate hypertension after 6 weeks of weekly gene administration. The applicability of hydrofection is truly wide and not only circumscribed to the liver, kidney, heart and muscle. Its use in the treatment of peritoneal endometriosis \[[@B122-genes-09-00136]\] has been evaluated in rats by intravenous injection of a delivery system composed of lipid-grafted chitosan micelles (CSO-SA) and the pigment epithelium derived factor (PEDF). The procedure significantly reduced the size of the endometrial lesions, atrophy and degeneration of ectopic endometrium, without toxic effects. In a model of liver failure in rats, researchers \[[@B123-genes-09-00136]\] injected *c-met* cDNA and observed transgene overexpression within the hepatocytes accompanied by proliferation enhancement, reduced apoptosis, as well as significant improvement in overall survival. In another study in rat kidney, efficiencies of adenoviral and baculoviral vectors were compared with the efficiency of naked DNA injection. Widespread fluorescent protein expression was observed for more than one month after transgene introduction. Plasmid and adenoviral vectors yielded gene transfer efficiencies ranging from 50--90%, compared with 10--50% mediated by baculovirus vector.

Liver hydrodynamic gene transfer is able to exert its therapeutic action both in liver and anywhere else in the organism. In this sense, the technique has been found to play an interesting role in the treatment of osteoporosis. The transfer of insulin-like growth factor 1 (IGF-1) gene in an ovariectomized rat model of osteoporosis showed remarkable expression of fluorescence, serum presence of IGF-1 and significant alleviation of osteoporosis. As an interesting approach to the treatment of mitochondrial diseases, Yasuzaki et al. \[[@B124-genes-09-00136]\] demonstrated that the hydrodynamic gene transfer of naked DNA could mediate gene access to the skeletal muscle mitochondrion after hind limb injection, opening an important field of research.

4.2. Rabbit to Pig {#sec4dot2-genes-09-00136}
------------------

The hydrodynamic procedure has achieved promising results in rodents. However, in order to allow clinical application, the translational process and its safety and efficiency had to be demonstrated in larger animals. The problem was that larger animals could not tolerate the demanding hemodynamic conditions of the injection. For this reason, different approaches designed to reduce the volume of gene solution have been proposed, such as targeting a specific organ or a segment of an organ by partially or completely excluding its vascularization.

In this regard, Eastman et al. \[[@B125-genes-09-00136]\] injected a reporter gene in rabbit liver using two strategies: (a) targeting a single liver lobe employing a balloon catheter; and (b) targeting the entire organ with hepatic venous occlusion. The authors achieved protein plasma expression over two days, with higher levels when the whole liver was targeted. The safety of liver hydrodynamic gene transfer was also assessed in dogs in order to assess its application to large animals \[[@B126-genes-09-00136]\]. Four successive injections of 250 mL of hAAT, FIX or Luciferase gene solution were made in four different main liver lobes and numerous variables were evaluated, such as transaminases and cytokines. The authors observed no significant harmful effects and recovery of the animals was rapid.

The following step in clinical translation of the procedure was to test its potential use in animals closer in size and anatomy to humans, such as pigs and primates.

Yoshino et al. \[[@B127-genes-09-00136]\] and Aliño et al. \[[@B128-genes-09-00136]\] independently described the first attempts in pigs. They reduced the total volume employed by targeting an area of liver and compared different delivery strategies mediated by catheterization. The strategies tested were: portal vein occlusion, left hepatic artery occlusion, portal vein and left hepatic artery occlusion and the occlusion of both vessels with blood flow washout. Yoshino et al. injected the gene solution (150 mL) carrying *eGFP* or *CTLA4-Ig* gene at 5 mL/s through the cava vein. Occlusion of the portal vein and hepatic artery with washout mediated the most efficient outcomes, achieving disperse fluorescence in liver tissue (due to *eGFP* gene) and CTLA4-Ig protein plasma levels for several weeks, with expression peaks of up to 161 ng/mL one day after treatment. This was the first time the procedure was described in pigs, yielding results of interest for proteins with low levels of expression. In another work, large and small areas of liver were targeted for retrovenous hydrofection in pigs. Aliño et al. \[[@B128-genes-09-00136]\] reported the presence of gene in liver tissue, as determined by semi-quantitative PCR. Protein expression was also observed by immunohistochemical evaluation in tissue, mainly within the perivenous area. This work also confirmed (by transmission electron microscopy) the previously described \[[@B17-genes-09-00136]\] formation of endocytic vesicles after hydrodynamic gene delivery in liver. On targeting smaller liver areas while injecting the same volumes of gene solution, the plasma protein levels two weeks after injection reached up to 200 ng/mL---such levels being much lower than those regarded as therapeutic. Fabre et al. \[[@B129-genes-09-00136]\] targeted the entire liver and isolated the hepatic segment of the inferior vena cava by clamping it supra- and infrahepatically. Gene solution (400 mL) was transferred at 100 mL/s through two parallel syringes and although the efficiency of gene delivery (measured by luciferase) was much lower than that observed in mouse and rat, the authors confirmed the clinical feasibility and safety of the technique as determined by systemic blood pressures, electrocardiography, heart rate, etc.

In parallel to the development of liver hydrofection in large animals, other possible applications of the procedure were also tested. In this regard, cardiac gene transfer by an adaptation of the hydrodynamic procedure was studied \[[@B18-genes-09-00136]\]. A naked *eGFP*-carrying plasmid was injected (50 mL; 20 μg/mL) through the coronary sinus at 5 mL/s employing a catheter, while another catheter fitted with a balloon was placed proximally within the sinus to block outflow. This procedure yielded efficient gene delivery (1--200 copies of gene per haploid genome), exhibiting a relative transcription rate with respect to the *GAPDH* gene of 0.2--10 mRNA copies. The expression of protein was observed by immunohistochemistry. That same year, the efficiency of the hydrodynamic procedure in application to skeletal muscle gene transfer in pigs \[[@B130-genes-09-00136]\] was demonstrated by the expression of luciferase after gene transfer (100 μg/mL) in the hind limb. In the hands of these authors, the injection of 300 mL (1.5% of body weight) of luciferase gene solution at 15 mL/s and 300 psi pressure yielded 10^6^--10^7^ RLU/mg of protein 5 days after injection and gene expression in transfected cells was maintained for two months. Given the important role of the pressure reached within the liver during hydrodynamic injection, Fabre et al. \[[@B131-genes-09-00136]\] focused on pressurizing individual liver lobes by excluding their vasculature. Seeking to achieve localized high-pressure levels without affecting the systemic circulation, these authors proposed individualizing the lobes by employing catheters with balloons and ligation. Luciferase gene (200 mL) was injected through individual branches of the portal vein to targeted liver lobes at 50 mL/s, with occlusion of their tributary suprahepatic cava vein and without occluding normal portal flow and cardiac load. This strategy allowed the reaching of intrahepatic pressure levels of up to 100 mmHg.

Although most authors have pointed to blood pressure as the most important feature of hydrodynamic injection in mediating efficient gene transfer, other investigators have described other characteristics of injection, such as impulse \[[@B84-genes-09-00136]\] and flow rate \[[@B132-genes-09-00136],[@B133-genes-09-00136]\], as being of relevance. In any case, almost all authors agree on the need or benefit of isolating target areas or the entire liver by vascular exclusion in order to improve the efficiency of the procedure. Such vascular isolation may be partial or complete. It had been previously reported that the complete liver vascularization of the pig could be occluded for up to 20 min without hepatic injury or systemic damage \[[@B134-genes-09-00136]\]. Based on this fact, Carreño et al. \[[@B132-genes-09-00136]\] described a surgical procedure for completely sealing the pig liver in vivo and performing the hydrofection targeted to the whole organ. An *eGFP* gene (20 μg/mL) saline solution (200 mL) was injected at 10, 20 and 60 mL/s simultaneously through the suprahepatic inferior cava vein and the portal vein using two catheters connected by a Y-connector and a high-volume pump. Optimal conditions were found to be the retrograde injection of 200 mL at 20 mL/s. Due to the invasiveness of the surgical procedure, same authors adapted this model for sealing the liver venous system through catheterization \[[@B21-genes-09-00136]\]. Two strategies ([Figure 3](#genes-09-00136-f003){ref-type="fig"}) were proposed and compared: (a) the use of a balloon catheter for insertion into a single lobe; and (b) the use of three catheters with balloons simultaneously placed within the supra- and infrahepatic inferior cava vein and in the portal vein, around entry to the liver. The procedure involving complete venous obstruction and entire organ targeting adopting the suprahepatic inferior cava vein route yielded greater gene delivery, transcription and translation in liver tissue 14 days after injection---achieving more than 10^5^ copies of hAAT protein per cell. However, the presence of protein in plasma was dramatically lower (more than 4 orders of magnitude)---a fact that could be due to differences between species. Catheterization-mediated hydrodynamic gene delivery in a single lobe was also used to compare the efficacies of the naked DNA and foamy viral vector strategies \[[@B135-genes-09-00136]\]. The *eGFP* gene was transferred in a naked plasmid and in a foamy viral vector. The presence and expression of *eGFP* was determined one week and one month after transfer by PCR and qPCR versus *GAPDH*, assessed as ΔΔCt. The authors recorded better outcomes using viral vector, with expression levels of up to 29.7% of the endogenous *GAPDH* levels.

Open procedure model (left panel): catheterization was carried out through the jugular vein with an 8 Fr balloon catheter placed in a suprahepatic branch.

Closed procedure model: The catheter-mediated liver vascular isolation was performed by simultaneous catheterization of the intrahepatic portal vein (transhepatic catheterization with a 10 Fr balloon catheter) and both the supra- and infrahepatic inferior cava vein (two 8 Fr balloon catheters through the jugular and femoral veins), with balloons limiting the perfusion area. This permitted excluding the entire liver venous vasculature.

4.3. Primates {#sec4dot3-genes-09-00136}
-------------

Different gene therapy attempts have been carried out in primates \[[@B93-genes-09-00136]\], with the aim of transferring genes to skeletal muscle, through the hind limb with occluded outflow. This strategy proved efficient for the expression of plasmid DNA and/or siRNA, as determined by luciferase quantification. Wooddell et al. \[[@B98-genes-09-00136]\] tested the expression efficacy of different LacZ tracer gene constructs driven by different promoters in mice, rats and rhesus monkeys. They determined the long-term (up to 49 weeks) expression of LacZ in mice, with better outcomes being recorded when employing the CMV promoter. Despite the different gene therapy studies carried out in primates, most of them \[[@B136-genes-09-00136],[@B137-genes-09-00136]\] have employed viral vectors to transfer genes to skeletal muscle and liver. However, the ethical implications, the lack of clinical response (possibly limited by viral particle size) and the difficulty of working with this animal model have limited its use and researchers have focused especially on pigs.

The applications of hydrodynamic gene therapy in middle to large size animals are summarized in [Table 2](#genes-09-00136-t002){ref-type="table"} and [Table 3](#genes-09-00136-t003){ref-type="table"}.

5. Parameters of the Genes Transfer Process {#sec5-genes-09-00136}
===========================================

The efficacy of gene transfer can be measured by different procedures and authors have studied many variables to present their results and evaluate how efficient a procedure is and how interesting it could be for clinical application. When the murine model and standard efficient hydrodynamic injection is employed, protein translation is efficient and quantifiable both within tissue (immunohistochemistry, Western blot, ELISA) and eventually also in the bloodstream (ELISA). After confirmation of the optimum response of hydrodynamic gene therapy in the murine model, the development of new animal models, different delivery strategies and gene constructs, etc. involving less efficacious protein production, required other parameters for the expression of results. In this regard, a detailed analysis was needed to establish the effectiveness of each stage of the gene decoding process. Such evaluation was able to identify the steps limiting the efficacy of the procedure. In this chapter, we suggest a quantitative manner of evaluating the molecular process of gene decoding that could facilitate the comprehension and reporting of gene expression results.

The molecular evaluation of decoding is mandatory for correct interpretation of the process. The determination of DNA, mRNA and protein can be qualitative, semi-quantitative or quantitative. Qualitative analyses only allow identification of the presence of a molecular species, without possible interpretation of the efficiency of the procedure, gene construct, etc. The semi-quantitative determination of nucleic acids has been widely employed and consists of expressing the relative amount of DNA or mRNA based on the presence of a housekeeping gene. This strategy has limitations that impede correct evaluation and comparison of different procedures, such as differences in the housekeeping genes employed or different gene expressions depending on the cell type and situation involved---thereby precluding the obtainment of real information on the amount of the specific molecular species. Western blot is used for the semi-quantitative determination of protein. This technique allows us to observe the presence and approximate amount of protein by comparison with other samples or purified protein in known quantities. Quantitative determination of the molecular process in turn affords real data on delivery, transcription and translation indexes expressed as the number of copies per cell of the respective molecular species. In the case of DNA and mRNA, real-time quantitative PCR is required. The data obtained for samples must be plotted on a standard curve prepared with a defined amount of the same gene construct injected. For protein quantitation, the ELISA technique with a standard curve prepared with serial dilutions of the purified protein is performed. By knowing the molecular weight of each molecular species, the exact number of molecules present in a unit volume and/or weight can be determined. Different reference units have been proposed: total protein weight, total organ weight, total DNA/RNA/protein, etc. In order to facilitate comparison of the results and objectively define the best conditions for gene transfer, authors should reach consensus on data quantitation and expression.

When a secretion protein is employed and its presence in plasma is evaluated, we suggest that the pharmacological term efficacy should be maintained, defined as the amount of protein in plasma per dose of DNA employed. The results should be expressed in molecular units (e.g. number of copies or moles) whenever possible or opportune, or alternatively in units of mass. This would make it possible to establish the optimum doses for potential treatment. We suggest evaluating the expression of transfected gene in a quantitative and objective manner, employing a universal standard reference. Since the cell is the biological reference unit, we consider that the amount of DNA, RNA and protein should be related to a normalized cell. When the results are evaluated in cultured cells or tissues, the data should be referred to a common circumstance such as a standard or "normalized cell." Such data make wide sense in the majority of studies from different areas. A normalized cell has been described \[[@B142-genes-09-00136]\] as having the following average characteristics: weight 3--4 ng with a volume of ≈1 pl and a diameter of ≈10 μm, depending on the cell type. The total protein content of a cell is ≈700 pg but the dynamic range of concentration can span up to 7 orders of magnitude \[[@B143-genes-09-00136]\]. The mass of genomic diploid DNA in a human cell is estimated to be ≈6.6 pg, whereas that of RNA is ≈10--20 pg \[[@B144-genes-09-00136]\].

A normalized diploid cell was classically described by Alberts et al. as a typical mammalian hepatocyte with a defined content of total DNA (genome weight of the specific animal, human: 6.6 pg), RNA (20 pg) and protein (500 pg)---and these are the parameters we employed as reference.

Three types of parameters can be used in seeking to objectively assess the efficiency of the gene transfer procedure step-by-step, minutely at molecular level: (a)Indexes, for the absolute number of copies of each molecular species (DNA, RNA or protein) referred to a normalized cell.(b)Intrinsic activities, representing the index ratio between consecutive steps (transcription (RNA/DNA) and translation (protein/RNA)) of the decoding process, in order to evaluate how efficient each step is, in a normalized cell.(c)Expression efficacy, defining the final efficacy of the procedure in the tissue relating the amount of protein copies per gene copy, in a normalized cell.

The formulas of each parameter can be defined as follows:

Index formulas:

**-** Delivery index: transgene DNA copy number/animal diploid genome weight. Example for humans:

Delivery index = X transgene copies/6.6 pg of total DNA

**-** Transcription index: transgene RNA copy number/20 pg of total RNA. Example for mammalian cells:

Transcription index = X transgene mRNA copies/20 pg total RNA

**-** Translation index: transgene protein copy number/500 pg of total protein. Example for mammalian cells:

Translation index = X transgene protein copies/500 pg total protein

Intrinsic activity formulas:

**-** Transcription activity: (transgene RNA copy number/20 pg of total RNA)/(transgene DNA copy number/animal diploid genome weight). Example for human cells:

Transcription activity = (X transgene mRNA copy number/20 pg of total RNA)/(X transgene DNA copy number/6.6 pg total DNA)

**-** Translation activity: (transgene protein copy number/500 pg of total protein)/(transgene RNA copy number/20 pg of total RNA). Example for mammalian cells:

Translation activity = (X transgene protein copy number/500 pg of total protein)/(transgene RNA copy number/20 pg of total RNA)

The efficacy of gene expression relates the protein translation index to the gene delivery index in order to define the global efficacy of the procedure.

The formulas referred to gene expression efficacy are defined as:

\- Expression efficacy: evaluated from organ tissue or cell culture.

Expression efficacy = (transgene protein copy number/500 pg of total protein)/(transgene DNA copy number/animal diploid genome weight)

\- Efficacy: evaluated from plasma or extracellular fluid. Classically, final efficacy is expressed as plasma concentration of protein (w/v) related to the dose of DNA (w) administered (protein (w/v)/DNA (w)). In order to easily relate this with the abovementioned parameters, the dose and concentration should be expressed in moles (protein (mol/v)/DNA (mol)).

Efficacy = concentration of protein (w/v)/dose of DNA (w) administered.

We consider this strategy to offer an objective and clear analysis that enables expression of the data as a ratio of copy number of each molecular species (regarding the usual content of DNA, RNA and protein) in a normalized cell. This offers a more comprehensive and visual interpretation of the entire process and allows comparison of the results from different works and research groups. Furthermore, the intrinsic activities and expression efficacy allow us to identify the limiting steps of the decoding process and establish optimum doses for treatment.

6. Hydrodynamic Genes Transfer to Human Organ Ex Vivo {#sec6-genes-09-00136}
=====================================================

The hydrodynamic procedure has been shown to be highly efficient in the murine model, achieving therapeutic plasma levels of human proteins of clinical interest. Clinical translation to larger animals has been partially disappointing in terms of final protein secretion. This lack of efficiency has been reported to be due to interspecies differences during protein folding and/or exportation. However, positive results in tissue gene decoding have been recorded, showing effective protein translation within liver tissue. The translational procedure in animal models has been completed and this limitation could only be circumvented by employing human tissue. Thus, application of the hydrofection strategy in human ex vivo models is justified, since this could complete the translational process prior to implementing a clinical trial. In the present chapter, different adaptations for employing human tissues as a target and solve the obvious limitations of in vitro models are described.

6.1. Isolated Human Organ Segments {#sec6dot1-genes-09-00136}
----------------------------------

Liver segments from surgical resection are a good option, since they have the required features for optimum hydrofection: the vasculature is preserved and catheters can be placed within them. Furthermore, retrograde injection through a suprahepatic vein can be performed and complete sealing is established due to the surgical intervention. Herrero et al. \[[@B145-genes-09-00136]\] employed such human liver segments to retrogradely inject a eGFP plasmid (20 μg/mL) driven by a CMV promoter through a short 9 Fr catheter placed in a suprahepatic vein. Different injection conditions were compared to establish the most appropriate ones: volumes equivalent to 1/5 or 1/10 segment weight and flow rates of 1, 10 and 20 mL/s.

Protein expression and tissue distribution, evaluated by fluorescent and immunohistochemistry studies, showed good and wide gene expression and the quantitative molecular analyses reinforce the histological findings. Employing similar human liver segments from surgical resection, Sendra et al. \[[@B146-genes-09-00136]\] hydrodynamically injected a volume equivalent to 1/5 of the liver segment weight of interleukin-10 plasmid solution (20 μg/mL) at 10 and 20 mL/s. Interleukin-10 protein is not produced naturally in liver and its levels within liver tissue are low. For this reason, the presence of IL10 protein within liver could be considered as produced by the plasmid hydrofection. Regarding the results previously reported by our group \[[@B147-genes-09-00136]\] in pig heart in vivo, the indexes referred to tissue IL-10 expression (over 100 copies/cell \[[@B145-genes-09-00136],[@B146-genes-09-00136]\]) could mediate local immunosuppressant pharmacological effects of interest for controlling the immune response (the IC50 of IL-10 for TNFα being 124 pg/mL \[[@B148-genes-09-00136]\]) triggered after liver transplantation.

This model allowed evaluation of the efficiency of human gene transfer and decoding in human liver tissue. Given the interest of this strategy for transferring genes to human organs, the human liver segment hydrofection procedure was adapted \[[@B149-genes-09-00136]\] to human colon segments. The segments from surgical tumour resection maintain the complete vasculature of the segment, allowing injection of the gene solution under hydrodynamic conditions. The *hIL-10* gene (20 μg/mL) solution was retrogradely injected in tumour-bearing colon segments (50 mL at 20 mL/s) and the presence of IL-10 DNA, RNA and protein was quantified. The procedure mediated a protein translation index in tissue of up to 1000 copies/cell---this being close to the values obtained in liver. As a preliminary experiment, one colon segment with inflammatory bowel disease was also used \[[@B149-genes-09-00136]\] to evaluate the potential interest of the procedure in treating disease. The procedure mediated similar levels of tissue protein translation (around 1000 molecules per cell). This production of protein could have immunosuppressant pharmacological effects of interest for the treatment of inflammatory disorders. The applications of hydrodynamic gene therapy in humans are summarized in [Table 4](#genes-09-00136-t004){ref-type="table"}.

The next step consists of employing this human organ segment model to transfer a human gene of clinical interest for treating disease. With this purpose in mind, we used the previously reported conditions to transfer the human *AAT* gene to human liver and evaluate its decoding efficiency in its target tissue. Aiming to completely differentiate between the protein encoded by the transferred gene and the endogenous AAT protein (with high rates of liver production), special gene constructs bearing an additional tracer (tag/flag) sequence of DNA with the ability to be transcribed and translated into synthetic mRNA and protein were required. In this regard, we have designed and constructed a plasmid containing the entire *hAAT* gene with a flag sequence (hAAT-flag) presenting an open reading frame to permit its transcription and translation. We have already conducted preliminary studies in four human liver segments, injecting this AAT gene plasmid containing the flag sequence (hAAT-flag), under the conditions used in other studies. After gene transfer, tissue samples were cultured at 37° under a 5% CO2 atmosphere in DMEM medium. The analyses of the gene decoding process showed efficient expression of hAAT-flag protein in liver tissue ([Table 5](#genes-09-00136-t005){ref-type="table"}). The amount of tagged protein (AAT-flag) accounted for close to 50% of total tissue AAT three days after gene transfer. This result proves that both endogenous and exogenous proteins were expressed with similar efficacy and that consequently the relative expression efficacy of exogenous protein is 100% when compared with the endogenous protein. This demonstrates that the hydrofection procedure could mediate efficacious protein expression after exogenous gene transfer in humans. The efficacy of protein export into the bloodstream from liver in order to exert systemic effects remains to be elucidated and further experiments and models would be required.

6.2. Future Perspectives: Isolated Organ with Continuous Vascular Perfusion and CRISPR Gene Edition {#sec6dot2-genes-09-00136}
---------------------------------------------------------------------------------------------------

Hydrodynamic liver gene therapy offers the possibility of treating systemic disorders due to the capacity of the liver to produce and release proteins into the bloodstream. Thus, a new model allowing the study not only of decoding but also of export should be developed. An isolated organ model with vascular perfusion and the possibility of keeping an entire human liver viable for a few days should allow us to evaluate the entire decoding process after hydrofection, from delivery to protein translation and export into the circulating medium. At present, different devices for maintaining liver circulation ex vivo are being used in the field of liver transplantation, such as Organox^®^ and other experimental systems have been proposed \[[@B159-genes-09-00136]\]. Our group has already designed and constructed a preliminary system offering the possibility of liver maintenance for up to two days for preclinical studies. The hAAT-flag plasmid could be used in human livers connected to a continuous perfusion machine, with evaluation of the secretion of a human exogenous protein by the human liver. Efficient expression and secretion of hAAT-flag protein in perfusion medium could constitute the last step in the translational process prior to use in a clinical trial.

Hydrodynamic procedure for gene transfer has normally been used for naked DNA transfection. However, this strategy could facilitate the delivery of other gene constructs containing viral and non-viral vectors. Hydrofection would permit overcoming the main limitation of the different strategies for genome editing or repair (Zinc fingers, TALENS). In recent years, a new strategy (CRISPR/Cas9) for genome editing in a customized and inexpensive manner has emerged \[[@B129-genes-09-00136],[@B130-genes-09-00136]\] and this technology is reaching many laboratories. Although is an efficient strategy for targeted genome edition, a number of limitations must be resolved---fundamentally the difficulty of delivery to target cells and/or organs. The great appearance of CRISPR/Cas9 and its wide application throughout the world gave a renewed interest to hydrodynamic gene transfer methodology. The hydrodynamic gene transfer could mediate the delivery of CRISPR/Cas9 constructs in vivo, both as plasmid and as ribonucleoprotein complex, as a safe and efficient procedure of transfection.
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![Hydrodynamic method. The figure shows the mouse normal blood flow and the effects mediated by hydrodynamic injection (indicated by a gap line within tail vein and from inferior vena cava to the liver through hepatic vein). Blood flows from tail vein to heart, who drives it to lungs to be oxygenated, returned to heart and distributed to the entire whole through aortic artery. The liver receives a profuse blood supply from the hepatic artery and portal vein. Blood flow from portal vein to inferior cava vein must cross the liver parenchyma through the hepatic sinusoids. When hydrodynamic injection is performed through tail vein, this large volume (2 mL) drains into inferior cava vein, it results in increased venous pressure that mediates retrograde blood flow into liver sinusoids (arrow with dashed line). This permits the gene accessing the liver. Employing different experimental strategies, the hydrofection mechanism has been suggested to involve transient inversion of intrahepatic blood flow and massive fluid endocytic vesicles in hepatocytes, mainly in those distributed around the central vein. The volume stays immobilized but pulsatile until heart, thanks to heart rate increasing, pumps this volume to bloodstream.](genes-09-00136-g001){#genes-09-00136-f001}

![Hydrofection mechanism. The figure shows the mechanism underlying the hydrofection gene transfer to the cells in liver. Upper panel shows a liver lobe unit (right) with its vascular system, which has been enlarged (left) to show the sinusoid vessel detail. Squared area is augmented in lower panel, where the sinusoid vessel organization is showed in detail just after hydrofection. It can be observed that retrovenous injection mediates hydrodynamic force that widens the vessel and virtual Disse space, separates endothelial cells and induces large number of endocytic vesicles on hepatocytes without obvious plasma membrane rupture It suggests that hydrodynamic force mediates DNA delivery to hepatocyte via diffusion process, involving a microfluid uptake process and/or penetration through facilitated permeable sites in the cell membrane. PV: portal vein; CV: Cava vein; HA: hepatic artery.](genes-09-00136-g002){#genes-09-00136-f002}

![Catheterization strategies for minimally invasive liver hydrofection 'in vivo.' Schematic representation of liver venous vasculature and catheters position. Continuous line represents extrahepatic vessels. Gapped lines represent intrahepatic vasculature. Grey arrows indicate the normal blood flow sense. Black thick arrows indicate the sense of hydrodynamic injection.](genes-09-00136-g003){#genes-09-00136-f003}
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Hydrodynamic gene transfer works performed in murine model. The table shows the author of each work, the publication year, the target organ assayed, gene and gene construction, conditions of hydrodynamic injection, experimental aim and methodology, disease of interest and effect duration.

  Author                                           Year   Organ                                        Gene                                                                                                                                                                                                                                   Gene Construct                                                               HD Variants                                                          Experimental Aim                                                                                                                 Disease                                                                                                                                                                                                                                                                Long-Term Expression
  ------------------------------------------------ ------ -------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------- -------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------
  Bell, J.B. \[[@B83-genes-09-00136]\]             2007   Liver                                        HemOxigenase-1, *LDLR*/*VLDLR*                                                                                                                                                                                                         SB Transposon                                                                HD                                                                   Transgene expression, qRT-PCR, Integration, Plasma presence, Clinic variables                                                    Method, Sickle-cell disease, Familial hypercholesterolemia                                                                                                                                                                                                             up to \>6 months
  Belcher, JD \[[@B50-genes-09-00136]\]            2010                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Hackett, P.B. \[[@B84-genes-09-00136]\]          2011                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Turunen TA \[[@B38-genes-09-00136]\]             2016                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Yang, PL \[[@B53-genes-09-00136]\]               2002   Liver                                        HBV                                                                                                                                                                                                                                    Sleeping beauty transposon-super genomic DNA                                 HD-HBV induction                                                     Histology, titration, southern blot, northern blot, PCR, ELISA                                                                   Hepatitis B                                                                                                                                                                                                                                                            20 days
  Doherty J \[[@B85-genes-09-00136]\]              2012   Liver/HEK293, HeLa, T cells                  Neomycin resistance, full length Factor VIII                                                                                                                                                                                           PiggyBac Transposon Vector cDNA                                              HD                                                                   Transgene expression, qPCR, clinical assays                                                                                      Method, Haemophilia A                                                                                                                                                                                                                                                  up to \>300 days
  Matsui H \[[@B36-genes-09-00136]\]               2014                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Chen, I.Y. \[[@B86-genes-09-00136]\]             2014   Liver/heart                                  *Luc*                                                                                                                                                                                                                                  Titrable two-step transcriptional amplification vector strategy              HD/intramyocardial injection                                         Fluc exp modulation by raloxifene-mediated activator                                                                                                                                                                                                                                                                                                                                                    
  Camassola M \[[@B46-genes-09-00136]\]            2005   Liver/syst                                   *IUDA*                                                                                                                                                                                                                                 Superfect complexes cDNA                                                     HD caudal vs. intraperitoneal                                        Activity, transgene expression, PCR                                                                                              Muccopolysacharidosis I                                                                                                                                                                                                                                                14 days
  Alino SF \[[@B1-genes-09-00136]\]                1994   Liver                                        *hAAT* (pTG7101)                                                                                                                                                                                                                       Small liposomes                                                              single & multiple dose + Partial HTx                                 ELISA & Liver Cytophotometry                                                                                                     15 days                                                                                                                                                                                                                                                                
  Zender, L \[[@B56-genes-09-00136]\]              2003   Liver, heart, vascular                       *Cas8, alpha-gal, antiviral, Fas, Cas8, GFP, OPN, nAchRalpha1, Apo-LP*                                                                                                                                                                 siRNA                                                                        Intraportal, aortic, in vitro                                        Luciferase, expression, Western Blot, ELISA, immunofluorescence, survival, virus titre, histochemistry                           Liver failure, Influenza, sepsis, hepatitis, transplantation, atherosclerosis                                                                                                                                                                                          up to 4 months
  Tompkins, SM \[[@B80-genes-09-00136]\]           2004                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Chu \[[@B87-genes-09-00136]\]                    2005                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Wesche-Soldato, DE \[[@B79-genes-09-00136]\]     2005                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Saito Y \[[@B57-genes-09-00136]\]                2007                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Zhang G \[[@B23-genes-09-00136]\]                2011                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Kim, S.I. \[[@B55-genes-09-00136]\]              2009                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Wesche-Soldato DE \[[@B88-genes-09-00136]\]      2008                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Huang M \[[@B62-genes-09-00136]\]                2013   Liver                                        *NKG2D, PTP1B*                                                                                                                                                                                                                         shRNA                                                                        HD                                                                   Cell count, histology, cytometry, Luciferase, Western Blot, qPCR, glucose levels                                                 Hepatitis, diabetes                                                                                                                                                                                                                                                    up to 10 days
  Vakili S \[[@B44-genes-09-00136]\]               2013                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Magnusson T. \[[@B89-genes-09-00136]\]           2011   Liver                                        *Luc*                                                                                                                                                                                                                                  Promoter: CMV-EF1a                                                           HD-tail vein                                                         Luciferase, qPCR                                                                                                                                                                                                                                                                                                                                                                                        up to 2 months
  Schuttrumpf J \[[@B35-genes-09-00136]\]          2011   Liver                                        FIX human                                                                                                                                                                                                                              Plasmid vs. minicircle                                                       HD                                                                   Expression, function, methylation                                                                                                Haemophilia B                                                                                                                                                                                                                                                          100 days
  Ando M \[[@B70-genes-09-00136]\]                 2014   Liver, kidney, muscle, lung, cells, tumour   *IFN-heparin binding domain, hAAT, hGF, PTH, alpha-Gal, hFIX, IFN-alb, hIL37, Luc, FcgammaR-Ig, PAP1, mIL10, mKATE, hKS, IL28B, mIL15+mIL15R, hGH, EPO, Distr, LacZ, VWF, Flk-1, UCP, Adiponectin, IGF, IFN-albumin binding peptide*   Plasmid DNA                                                                  HD, retro-orbital, hind limb, im, kidney injection, saphenous vein   Serum concentration, expression, ELISA, qPCR, Western Blot, histology, Luciferase, glucose levels, injury, electron microscopy   Cancer, hAAT deficiency, hypophysectomised, hypoparathyroidism, Fabry disease, Haemophilia B, metastasis, hepatitis, pancreatitis, obesity, dystrophy, inflammation, hGH deficiency, streptococcus infection, method, Von Willebrand disease, diabetes, nerve injury   up to \>8 months
  Zhang G \[[@B4-genes-09-00136]\]                 2000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Sondergaard, M \[[@B75-genes-09-00136]\]         2003                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Lee S \[[@B76-genes-09-00136]\]                  2008                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Nakamura G \[[@B82-genes-09-00136]\]             2008                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Kim H.S. \[[@B34-genes-09-00136]\]               2011                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Miyakawa N. \[[@B67-genes-09-00136]\]            2011                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Bulau, AM \[[@B59-genes-09-00136]\]              2011                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Yan S \[[@B90-genes-09-00136]\]                  2012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Shashidharamurthy, R \[[@B60-genes-09-00136]\]   2012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Shigekawa, M \[[@B91-genes-09-00136]\]           2012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Gao M \[[@B10-genes-09-00136]\]                  2013                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Guess, MG \[[@B25-genes-09-00136]\]              2013                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Lu S.L. \[[@B81-genes-09-00136]\]                2013                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Qiu C \[[@B74-genes-09-00136]\]                  2014                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Sun H \[[@B73-genes-09-00136]\]                  2016                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Wolff, JA \[[@B6-genes-09-00136]\]               1990                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Dagnaes-Hansen, F \[[@B92-genes-09-00136]\]      2002                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Alino, SF \[[@B5-genes-09-00136]\]               2003                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Hagstrom, JE \[[@B93-genes-09-00136]\]           2004                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Zhang, G. \[[@B94-genes-09-00136]\]              2004                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Crespo, A \[[@B17-genes-09-00136]\]              2005                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Pergolizzi, RG \[[@B49-genes-09-00136]\]         2006                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Yazawa, H \[[@B66-genes-09-00136]\]              2006                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Gonzalez-Muniesa, P \[[@B40-genes-09-00136]\]    2006                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Fukushima, M \[[@B42-genes-09-00136]\]           2007                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Li, W. \[[@B95-genes-09-00136]\]                 2008                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Schuttrumpf, H \[[@B32-genes-09-00136]\]         2008                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Suda T \[[@B96-genes-09-00136]\]                 2008                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Podetz-Pedersen, KM \[[@B97-genes-09-00136]\]    2010                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Xu, JF. \[[@B58-genes-09-00136]\]                2010                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Herrero, M.J. \[[@B31-genes-09-00136]\]          2011                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Ma, Y \[[@B43-genes-09-00136]\]                  2013                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Miyakawa, N. \[[@B69-genes-09-00136]\]           2013                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Wooddell, C \[[@B98-genes-09-00136]\]            2011                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Nagata, K \[[@B27-genes-09-00136]\]              2014                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  He, C \[[@B41-genes-09-00136]\]                  2004   Liver/Skeletal Muscle                        *Insulin, hGF, IL6, IFNg, mFGF21, SGSH, IL6-RFP-Fc, IL6*                                                                                                                                                                               Plasmid cDNA                                                                 HD, im                                                               Expression, plasma protein, immunohistology, clinical analysis, pathology, qPCR, WB, ELISA                                       Diabetes type 1 and 2, obesity, glomerulonephritis, dermatitis, MPSIIIA, inflammation                                                                                                                                                                                  up to 120 days
  Bu, X \[[@B99-genes-09-00136]\]                  2011                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Mukumoto, H \[[@B26-genes-09-00136]\]            2013                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Watcharanurak, K \[[@B78-genes-09-00136]\]       2013                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Baribault, H. \[[@B45-genes-09-00136]\]          2014                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Gao, M \[[@B11-genes-09-00136]\]                 2014                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Quiviger, M \[[@B48-genes-09-00136]\]            2014                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Gortz, D \[[@B63-genes-09-00136]\]               2015                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Ma, Y \[[@B12-genes-09-00136]\]                  2015                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Duguid, JG \[[@B100-genes-09-00136]\]            1998   Cell lines                                   *b-Gal, hGH, eGFP*                                                                                                                                                                                                                     Peptide/DNA pH sensitive, PEI & DOTAP/DNA complexes                          in vitro                                                             Cytochemistry, g-gal chemoluminiscence, fluorimetry, electrofluorescence, TEM, cytofluorescence, dynamics of gene transfer                                                                                                                                                                                                                                                                              14 days
  Moret, I \[[@B101-genes-09-00136]\]              2001                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Alino, SF \[[@B102-genes-09-00136]\]             2000   PD:D-R, Em, EC50, Pot, Afin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Alino, SF \[[@B28-genes-09-00136]\]              1993   Liver                                        *hAAT*                                                                                                                                                                                                                                 Large/small liposomes, Liposomes (-)vs(+) plus                               iv, HTx                                                              Cytophotometry, DNA, Size Distribution, ELISA                                                                                                                                                                                                                                                                                                                                                           up to 5 months
  Alino, SF \[[@B5-genes-09-00136]\]               1993                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Alino, SF \[[@B29-genes-09-00136]\]              1996                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Crespo, J \[[@B2-genes-09-00136]\]               1996                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Budker, V \[[@B7-genes-09-00136]\]               1996   Liver                                        *b-Gal, hGH*                                                                                                                                                                                                                           Naked                                                                        DNA, hypertonic solution-portal injection, hepatic vein occlusion    ELISA & histology                                                                                                                                                                                                                                                                                                                                                                                       2 days
  Xu, Z.X. \[[@B103-genes-09-00136]\]              2009   Liver                                        *hFIX*, *hAAT*                                                                                                                                                                                                                         Integrative DNA plasmid                                                      HD                                                                   Specific insertion, plasma concentration, toxicity, expression, IHC                                                              Haemophilia B                                                                                                                                                                                                                                                          up to 250 days
  Keravala, A. \[[@B33-genes-09-00136]\]           2011                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Ando, M \[[@B68-genes-09-00136]\]                2012   Liver                                        *IFN*                                                                                                                                                                                                                                  pDNA varying CpG motifs number                                               HD                                                                   Expression                                                                                                                       Cancer                                                                                                                                                                                                                                                                 
  Viecelli HM \[[@B51-genes-09-00136]\]            2014   Liver                                        *mPAH*                                                                                                                                                                                                                                 Minicircular cDNA                                                            HD                                                                   Expression serum and tissue, qPCR, histology                                                                                     Phenylketonuria                                                                                                                                                                                                                                                        \>1 year
                                                          Liver                                        HCV, others                                                                                                                                                                                                                            Genomic RNA-HCV internal ribosome entry site firefly luciferase, Non-viral   HD-HCV model                                                         Histology, Luciferase                                                                                                            Hepatitis C                                                                                                                                                                                                                                                            10 days
  McCaffrey, AP \[[@B54-genes-09-00136]\]          2002                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Habbitt, OC \[[@B104-genes-09-00136]\]           2007   Liver                                        gDNA (100 kb), *eGFP*, *LDLR*                                                                                                                                                                                                          gDNA, GenomicGenes, BAC                                                      HD                                                                   Efficacy vs. DNA copy number                                                                                                     Cholestrolemia                                                                                                                                                                                                                                                         4 months
  Okumura, A \[[@B77-genes-09-00136]\]             2008   Liver                                        *LECT2*                                                                                                                                                                                                                                Expression vector non-viral                                                  HD                                                                   Inflammatory expression, histopathology, PCR                                                                                     Arthritis                                                                                                                                                                                                                                                              12 days
  Zhang, G \[[@B22-genes-09-00136]\]               2010   Muscle                                       full-length Dystrophin Gene                                                                                                                                                                                                            Full length DNA                                                              HD-limb vein                                                         Distribution, expression, myofibres damage, Western Blot                                                                         Duchene                                                                                                                                                                                                                                                                
  Shahaf, G \[[@B105-genes-09-00136]\]             2011   Liver                                        *hAAT*                                                                                                                                                                                                                                 Epstein Bar Virus-plasmid                                                    HD                                                                   Islet function, Treg, macrophage, IL1                                                                                            Islet allogenic transplant                                                                                                                                                                                                                                             up to 100 days
  Ochoa, M \[[@B71-genes-09-00136]\]               2012   Liver                                        *IL15+ApoA1+IL15Ra*                                                                                                                                                                                                                    Expression plasmid cDNA                                                      HD                                                                   Cell count, pathology, Western Blot, PCR, cytometry                                                                              Cancer                                                                                                                                                                                                                                                                 60 days
  Holm, DA \[[@B37-genes-09-00136]\]               2003   Liver                                        *SCAD*, promoter genomic elements                                                                                                                                                                                                      cDNA                                                                         HD, in vitro                                                         Plasma protein, NK reconstitution, toxicity                                                                                      Metabolic disease                                                                                                                                                                                                                                                      31 days
  Barao, I \[[@B72-genes-09-00136]\]               2011   Immunodeficiency and transplantation         18 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Hibbit, O. \[[@B106-genes-09-00136]\]            2011                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Dasi, F \[[@B3-genes-09-00136]\]                 2001   Liver, Plasma                                *hAAT*                                                                                                                                                                                                                                 ASF-Lp, PS, DOTAP, NLS                                                       iv + Partial HTx                                                     ELISA, PCR, Sequencing                                                                                                           hAAT deficiency                                                                                                                                                                                                                                                        6 months & 12 months
  Wooddell, CI \[[@B107-genes-09-00136]\]          2008   Liver                                        Alkaline Phosphatase Reporter gene                                                                                                                                                                                                     Albumin promoter                                                             HD                                                                   Plasma protein                                                                                                                   Method                                                                                                                                                                                                                                                                 Albumin 1 year vs. CMV 1 day

genes-09-00136-t002_Table 2

###### 

Hydrodynamic gene transfer works performed in mid-size animals. The table shows the author of each work, the publication year, the animal model studied, the target organ assayed, gene and gene construction, injection methodology, variables evaluated, disease of interest and effect duration.

  Author                                         Year   Species                     Organ                   Gene                                                            Gene Construct                                 Methodology                                                      Variables                                   Disease              Long-Term Expression
  ---------------------------------------------- ------ --------------------------- ----------------------- --------------------------------------------------------------- ---------------------------------------------- ---------------------------------------------------------------- ------------------------------------------- -------------------- -------------------------------
  Budker, V \[[@B8-genes-09-00136]\]             1998   Rat                         Muscle                  *b*-*Gal*, luciferase                                           Naked, Solution hypo/hypertonic                Artery injection High pressure (hind-limb)                       Histochemistry, Luciferase                  2 days               
  Eastman, SJ \[[@B125-genes-09-00136]\]         2002   Rabbit                      Liver                   Alkaline Phosphatase Reporter gene                              DNA                                            HD catheter lobar and whole liver                                Plasma Alkaline Phosphatases                Model                2 days
  Hagstrom, JE \[[@B93-genes-09-00136]\]         2004   Mouse, Rat, Dog, Primate    Muscle                  DNA *Luc* vs. Ad; *EPO*; *Distr*                                DNA, siRNA, Ad                                 HD vein limb                                                     Luciferase                                  30 days              
  Inoue, S \[[@B109-genes-09-00136]\]            2004   Rat                         Liver                   *b-Gal, luc-image, CTLA4Ig*                                     DNA dosing CTLA4Ig                             HD system and local- catheter                                    Transplantation                             2 days               
  Zhang, X \[[@B113-genes-09-00136]\]            2004   Rat                         Liver                   Luciferase                                                      DNA                                            HD vs. regional Portal                                           Luciferase                                  Method               short
  Tosoulfas, G \[[@B117-genes-09-00136]\]        2006   *hAAT, Luc*                 DNA                     HD ex vivo DNA injection IVC closed                             Injury, histopathology, physiology, efficacy   Transplantation                                                  \>5 days                                                         
  Chang, H. \[[@B115-genes-09-00136]\]           2008   *IL10*-Ig fusion gene       DNA                     IL-17, IL1beta, TNFa, IL1...                                    Myocarditis                                                                                                                                                                      
  Suda, T \[[@B96-genes-09-00136]\]              2008   Mouse, Rat, Pig             Liver, Kidney, Muscle   *Luc, GFP, Ad-GFP*                                              DNA, Ad                                        HD computer assisted                                             Pressure, gene delivery/expression                               
  Xing, Y \[[@B119-genes-09-00136]\]             2009   Rat                         Kidney                  *Luc, EPO*                                                                                                     HD and ultrasound combination                                    Method                                                           
  Sawyer, GJ \[[@B120-genes-09-00136]\]          2010   Rat                         Liver                   *Luc*                                                           DNA                                            HD-Regional Lobe without occlusion                               Efficacy, luciferase activity               Method               
  Wooddell, C \[[@B98-genes-09-00136]\]          2011   Mouse, Rat, Rhesus monkey   Muscle                  *LacZ*                                                          Plasmid DNA complexes                          HD hind limb                                                     Expression and delivery                     null                 49 weeks
  Cim, A \[[@B121-genes-09-00136]\]              2012   Rat                         Liver                   *Pdx1, Ngn3, MafA*                                              5 different expression plasmids                HD                                                               Expression, PCR, IHC                        Diabetes type 1      28 days
  Romero-Vasquez, F \[[@B138-genes-09-00136]\]   2012   Rat                         Liver                   hepatocyte growth factor                                        pCMV                                           HD                                                               NFkB, RANTES, MCP1, IL6, oxidative stress   Renal hypertension   6 weeks with weekly treatment
  Zhao, M \[[@B122-genes-09-00136]\]             2012   Rat                         Endometrium             pigment epithelium derived factor                               Polymeric micelle                              intravenous injection                                            Clinic observation of endometrium lesions   Endometriosis        
  Corridon, PR \[[@B139-genes-09-00136]\]        2013   Rat                         Kidney                  *eGFP, eGFP-actin/occluding/tubulin, tdTomato-H2B, RFP-actin*   Plasmid, adenovirus, baculovirus               HD retrograde renal vein                                         Expression-intravital, confocal             1 month              
  De La Vega, J \[[@B140-genes-09-00136]\]       2013   Chinese hamster             Ovary cells             *GFP*                                                           Plasmid lipofectamine lipoplexes               Methods of plasmid purification                                  Hydrodynamic diameter and zeta potential                         
  Yasuzaki, Y \[[@B124-genes-09-00136]\]         2013   Rat                         Muscle                  *Luc*                                                           DNA                                            HD-hindlimb                                                      Expression, luminescence, qPCR, WB          Method               24 h
  Kamimura, K \[[@B126-genes-09-00136]\]         2014   Dog/Rat                     Liver                   *Luc, hAAT, hFIX*                                               Plasmid cDNA/DNA                               HD-through hepatic veins of each 4 lobes with closed cava vein   Histology, physiological parameters         6 weeks              

genes-09-00136-t003_Table 3

###### 

Hydrodynamic gene transfer works performed in large animals. The table shows the author of each work, the publication year, the animal model studied, the target organ assayed, gene and gene construction, injection methodology, variables evaluated, disease of interest and effect duration.

  Author                                      Year   Species                     Organ                     Gene                           Gene Construct                             Methodology                              Variables                                              Disease             Long-Term Expression
  ------------------------------------------- ------ --------------------------- ------------------------- ------------------------------ ------------------------------------------ ---------------------------------------- ------------------------------------------------------ ------------------- --------------------------
  Hagstrom, JE \[[@B93-genes-09-00136]\]      2004   Mouse, Rat, Dog, Primate    Muscle                    *DNA Luc vs. Ad; EPO; Distr*   DNA, siRNA, Ad                             HD vein limb                             Luciferase                                             30 days             
  Yoshino, H \[[@B127-genes-09-00136]\]       2006   Pig                         Liver                     *GFP*, *CTLA4*-Ig              DNA                                        HD-cathe, closed (3 mg,150 mL, 5 mL/s)   Physiology, histology, fluorescence, plasma presence   Method              1 day (161 ng/mL)-7 days
  Alino, SF \[[@B128-genes-09-00136]\]        2007   Pig                         Liver (small vs. Large)   *hAAT*                         DNA                                        HD-Cathe, open (100 mL, 7.5 mL/s)        ELISA, IHC, injury, qRT-PCR                            hAAT deficiency     15 days (200 ng/mL)
  Fabre, JW \[[@B129-genes-09-00136]\]        2008   Pig                         Liver                     *pGL3* plasmid, *Luc*          DNA                                        HD-isolated segment of IVC               Pressure, ECG, heart rate, luciferase activity         Method              1 day
  Suda, T \[[@B96-genes-09-00136]\]           2008   Mouse, Rat, Pig             Liver, Kidney, Muscle     *Luc, GFP, Ad-GFP*             ADN, Ad                                    HD computer assisted                     Pressure, gene delivery/expression                                         
  Aliño, SF \[[@B18-genes-09-00136]\]         2010   Pig                         Heart                     *EGFP, GAPDH*                  Naked                                      HD Cath Coronary sinus                   IHC, PCR, RT-PCR, copy number                          Method              1 day
  Kamimura, K \[[@B130-genes-09-00136]\]      2010   Pig                         Muscle                    *pCMV-Luc*                     DNA                                        HD hindlimb                              Luciferase activity \[[@B95-genes-09-00136]\]          Method              60 days
  Fabre, JW \[[@B131-genes-09-00136]\]        2011   Pig                         Liver segment             *Luc*                          DNA                                        Surg-HD-LivSeg portal vs. hepat vein     Vascular pressure (\>100 mmHg)                         Method              Short
  Hackett, PB \[[@B84-genes-09-00136]\]       2011   Small&Large animals/Rev     Liver                     *Luc*                          Sleeping Beauty Transposon                 HD                                       Integration, Plasma presence                                               
  Wooddell, C \[[@B98-genes-09-00136]\]       2011   Mouse, Rat, Rhesus monkey   Muscle                    *LacZ*                         Plasmid DNA complexes                      HD hind limb                             Expression and delivery                                49 weeks            
  Carreño, O \[[@B132-genes-09-00136]\]       2013   Pig                         Liver                     *eGFP*                         Plasmid cDNA                               Surgery isolation, HD simultaneous       Expression PCR                                         1 day               
  Zacharoulis, D \[[@B135-genes-09-00136]\]   2013   Pig                         Liver                     *eGFP*                         Plasmid DNA vs. foamy virus vector-based   HD                                       Gene expression and qPCR                               1 week to 1 month   
  Sendra, L \[[@B133-genes-09-00136]\]        2014   Pig                         Liver                     *eGFP*                         Plasmid cDNA                               HD-surgical isolation cava vs. porta     Gene and protein expression, qPCR, ELISA, TEM          1 day               
  Kamimura, K \[[@B141-genes-09-00136]\]      2015   Small and large animals     Liver                     Various                        Non-viral                                  HD                                                                                              Various             
  Sendra, L \[[@B19-genes-09-00136]\]         2016   Pig                         Liver                     *hAAT*                         Plasmid DNA                                HD-open vs. closed catheterism           Tissue expression qPCR, ELISA, clinic observations     hAAT deficiency     14 days
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###### 

Expression of hAAT-flag in human liver segments after hydrodynamic gene transfer. Preliminary results of hAAT-flag protein expression in human liver tissue after the hydrodynamic delivery of its gene. The first column of the table shows the number of human liver segment (HL1-4), second column indicates the total amount of hAAT protein in liver tissue (including hAAT and hAAT-flag) expressed in copy number per cell. The third column shows the specific amount of hAAT-flag protein. The fourth column represents the ratio between the amount of hAAT-flag protein respect to the total amount of hAAT as percentage.

  Human Liver   Total hAAT (copy/cell)   hAAT-flag (copy/cell)   hAAT-f/Total hAAT (%)
  ------------- ------------------------ ----------------------- -----------------------
  1             7.16 × 10^5^             3.89 × 10^5^            54.31
  2             8.98 × 10^5^             5.31 × 10^5^            59.18
  3             9.62 × 10^5^             1.97 × 10^5^            20.46
  4             4.03 × 10^5^             2.43 × 10^5^            60.13
  Average       1.65 × 10^5^             8.86 × 10^5^            48.52
  sd            1.59 × 10^5^             1.04 × 10^5^            18.88
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###### 

Hydrodynamic gene transfer works performed in human models. The table shows the author of each work, the publication year, the human model studied, the target cell or organ assayed, gene and gene construction, injection methodology, variables evaluated, disease of interest and effect duration.

  Author                                       Year   Model              Organ/Cell                        Gene                           Gene Construct                          Methodology                           Variables                                                             Disease              Long-Term Expression
  -------------------------------------------- ------ ------------------ --------------------------------- ------------------------------ --------------------------------------- ------------------------------------- --------------------------------------------------------------------- -------------------- ----------------------
  Guillem, V \[[@B150-genes-09-00136]\]        2002   Human              Lymphoid cell line                *ODN*-FITC                     CD3-PEI/ODN-                            In vitro                              Fluorescence, Cells increase                                          Method               
  Guillem, V \[[@B151-genes-09-00136]\]        2002   Human              Jurkat & Granta                   *eGFP*                         CD3-PEI/eGFP                            In vitro                              Selective gene delivery                                               Method               
  Lledo, S \[[@B152-genes-09-00136]\]          2005   Human              Cell line SW480                   ASO-*Kras*                     ASO phosphorotioates                    In vitro                              Cell viability                                                        Cancer: colorectal   72 h
  Lee, S \[[@B76-genes-09-00136]\]             2008   mouse/human cell   Liver                             PTH                            Plasmid DNA                             HD                                    Plasma protein, expression                                            Hypoparathyroidism   
  Diaz-Moscoso, A \[[@B153-genes-09-00136]\]   2011   Human, Mouse       Macrophage                                                       80 nm manosilted cyclodextrin/DNAplex   In vitro                              Delivery, FACS                                                                             
  Doherty, J \[[@B85-genes-09-00136]\]         2012   Mouse/Human cell   Liver/HEK293, HeLa, T cells       Neomycin resistance cassette   transposone-piggybac                    HD                                    Transgene expression                                                                       6 months
  Herrero, MJ \[[@B145-genes-09-00136]\]       2012   Human              Liver                             *eGFP*                         pCMV                                    HD                                    Expression, PCR, fluorescence, IHC                                                         2 days
  Taniyama, Y \[[@B154-genes-09-00136]\]       2012   Human              Heart                             Various                        Plasmid                                 physical procedures                                                                                         Various              
  Balbino, TA \[[@B155-genes-09-00136]\]       2013   Human cells        HeLa                                                             Cationic liposomes                      Microfluidic systems comparison       Complex size, non-electrostatic bond, accessibility level                                  
  Sevimli, S \[[@B156-genes-09-00136]\]        2013   Human              Cells HepG2, H460, SHEP, MRC5     *GFP*                          Anionic and cationic polymers-siRNA     Transfection                          Diameter, potential, stability, qPCR, WB, flow cytometry, confocal                         
  Matsui, H \[[@B36-genes-09-00136]\]          2014   Mouse/Human cell   Liver/HEK293                      Full length Factor VIII        PiggyBac Transposon Vector cDNA         HD                                    Expression, PCR, qPCR, Coagulation assays                             Haemophilia A        \>300 days
  Heller, R \[[@B157-genes-09-00136]\]         2015   Human              Various                           Various                        Non-viral                               Electroporation                       Clinical trials                                                       Various              
  Mendrek, B \[[@B158-genes-09-00136]\]        2015   Human              Cell line HT1080 (fibrosarcoma)                                  Plasmid-polyplex                        Polyplexes DMAEMA (+) vs. DEGMA (0)   Hydrodynamic size, z potential, cytotoxicity, transfection efficacy                        
